Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.57 |
| ▸ | ACKR3 | P25106 | 7/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | ESRRA | P11474 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30398961 | 0.85 | CA1 (0.59) | CA1CA2CA9CA4ACKR3 | |
| SCHEMBL27877288 | 0.84 | ESRRA (0.57) | CA1CA2CA9CA4ESRRA | |
| SCHEMBL69876 | 0.84 | ESRRA (0.62) | CA1CA2CA9CA4NOTUM | |
| SCHEMBL2330243 | 0.83 | CA1 (0.57) | CA1CA2CA9CA4NOTUM | |
| SCHEMBL11902351 | 0.83 | CA1 (0.57) | CA1CA2CA9CA4NOTUM | |
| SCHEMBL28801446 | 0.82 | ESRRA (0.60) | CA1CA2CA9CA4NOTUM | |
| SCHEMBL14532856 | 0.82 | S1PR1 (0.50) | CA1CA2CA9ACKR3ESRRA | |
| SCHEMBL15578683 | 0.82 | CA1 (0.60) | CA1CA2CA9CA4NOTUM | |
| SCHEMBL243268 | 0.82 | GPR119 (0.47) | CA1CA2CA9CA4NOTUM | |
| SCHEMBL27911606 | 0.81 | CA1 (0.56) | CA1CA2CA9CA4NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-11691992-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210253605-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | ANACOR PHARMACEUTICALS INC (US) | 2021-08-19 | — | — | US | disclosed |
| US-10961261-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| EP-2895478-B1 | TRIAZOLE CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-9416127-B2 | Triazole carboxamides and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2016-08-16 | — | — | US | disclosed |
| EP-2895478-A1 | TRIAZOLE CARBOXAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-07-22 | — | — | EP | disclosed |
| US-20150191458-A1 | TRIAZOLE CARBOXAMIDES AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2015-07-09 | — | — | US | disclosed |
| CN-104603129-A | Triazole carboxamide derivatives | HOFFMANN LA ROCHE | 2015-05-06 | — | — | CN | disclosed |
| WO-2014041106-A1 | TRIAZOLE CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-20 | — | — | WO | disclosed |
| CN-102036558-A | Novel piperidine derivatives as stearoyl-CoA desaturase inhibitors | FOREST LAB HOLDINGS LTD | 2011-04-27 | — | — | CN | disclosed |
| WO-2010075356-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191458-A1 | TRIAZOLE CARBOXAMIDES AND USES THEREOF | TAAR1, HCRTR1, TAAR5 | CA1 2431/4885CA2 1361/4885CA9 3263/4885 |
| US-11691992-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | CA1 1411/4885CA2 914/4885CA9 2004/4885 |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | CA1 1867/4885CA2 437/4885CA9 2770/4885 |
| US-20210253605-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | OXA1L, AOX1, EPX | CA1 2840/4885CA2 1841/4885CA9 3215/4885 |
| US-10961261-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | CA1 1411/4885CA2 914/4885CA9 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.